Table 8.
Sensitivity analysis of uncertain parameters on the overall costs
| Baseline total cost (USDa) | Min | Max |
|---|---|---|
| 622,860.78 | 645,372.68 | |
| Parameter | Low parameters estimate effect (USDa) | High parameters estimate effect (USDa) |
| Disease rate: | ||
| Low endemicity area | 52,686 | 59,182 |
| Moderate endemicity area | 263,812 | 277,501 |
| High endemicity area | 1,544,794 | 1,583,129 |
| Hospitalization in the ward: | ||
| At health centre: | 622,380 | 664,128 |
| At district hospital: | 622,407 | 655,617 |
| RDTb | 606,695 | 744,050 |
| Blood smear | ||
| At health centre: | 597,430 | 685,993 |
| At district hospital: | 622,841 | 645,545 |
| ACTc | ||
| 6 × 1d | 614,174 | 752,363 |
| 6 × 4e | 609,406 | 1,026,020 |
| Artesunate | 620,485 | 649,575 |
| Lowest and highest economic impact1 | 549,169 | 1,343,601 |
aUSD: United States Dollar; bRDT: Rapid diagnostic test, cACT: Artemisinin-based combination therapy; c6 × 1: dosage for children with 5 kg to < 15 kg body weight; d6 × 4: dosage for adult and children with > 35 kg body weight; 1Lowest and highest economic impact: overall effect on total costs produced by varying all low cost and high-cost estimates simultaneously